Menu
 
Research menu
Jump to menu

Publications:  Dr Stephanie Kermorgant

Hervieu A, Kermorgant S(2018). The Role of PI3K in Met Driven Cancer: A Recap. Front Mol Biosci vol. 5,
10.3389/fmolb.2018.00086
Badreldin W, Powles T, Menard L, Ho-Yen C, Kermorgant S (2017). Understanding and targeting Met signalling in bladder cancer. ANNALS OF ONCOLOGY. vol. 28,
Barrow-McGee R, Kishi N, Joffre C, Ménard L, Hervieu A, Bakhouche BA, Noval AJ, Mai A et al.(2016). Corrigendum: Beta 1-integrin-c-Met cooperation reveals an inside-in survival signalling on autophagy-related endomembranes. Nat Commun vol. 7, 12392-12392.
10.1038/ncomms12392
BRENNAN CH(2016). Beta 1-integrin–c-Met cooperation reveals an inside-in survival signalling on autophagy-related endomembranes. Nature Communications vol. 7, 11942-11942.
10.1038/ncomms11942
Barrow-McGee R, Kishi N, Joffre C, Ménard L, Hervieu A, Bakhouche BA, Noval AJ, Mai A et al.(2016). Beta 1-integrin–c-Met cooperation reveals an inside-in survival signalling on autophagy-related endomembranes. Nature Communications vol. 7, 11942-11942.
10.1038/ncomms11942
Mofta H, Dias K, Hoque Apu E, Liu L, Uttagomal J, Bergmeier L, Kermorgan S, Wan H(2016). Desmoglein 3 regulates membrane trafficking of cadherins, an implication in cell-cell adhesion. Cell Adhesion & Migration
10.1080/19336918.2016.1195942
Moftah H, Dias K, Apu EH, Liu L, Uttagomol J, Bergmeier L, Kermorgant S, Wan H(2016). Desmoglein 3 regulates membrane trafficking of cadherins, an implication in cell-cell adhesion. Cell Adhesion and Migration1-22.
10.1080/19336918.2016.1195942
Hervieu A, Kermorgant S(2015). PI3K class I and mTOR regulate distinct steps in Met dependent tumorigenesis. MOLECULAR CANCER THERAPEUTICS vol. 14, (7)
10.1158/1538-8514.PI3K14-B26
Ho-Yen CM, Jones JL, Kermorgant S(2015). The clinical and functional significance of c-Met in breast cancer: a review. Breast Cancer Res vol. 17,
10.1186/s13058-015-0547-6
Moftah H, Diaz K, Kermorgant S, Wan H (2014). Role for Desmoglein 3 in regulating E-cadherin trafficking. JOURNAL OF INVESTIGATIVE DERMATOLOGY. vol. 134, S29-S29.
Hervieu A, Joffre C, Leung Z, Kermorgant S(2014). Understanding and targeting PI3K pathway downstream of Met oncogenic mutant. EUROPEAN JOURNAL OF CANCER vol. 50, S115-S115.
10.1016/S0959-8049(14)50424-8
Ménard L, Parker PJ, Kermorgant S(2014). Receptor tyrosine kinase c-Met controls the cytoskeleton from different endosomes via different pathways. Nat Commun vol. 5,
10.1038/ncomms4907
Mai A, Muharram G, Barrow-McGee R, Baghirov H, Rantala J, Kermorgant S, Ivaska J(2014). Distinct c-Met activation mechanisms induce cell rounding or invasion through pathways involving integrins, RhoA and HIP1. J Cell Sci vol. 127, (Pt 9) 1938-1952.
10.1242/jcs.140657
Barrow-McGee R, Kermorgant S(2014). Met endosomal signalling: In the right place, at the right time. INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY vol. 49, 69-74.
10.1016/j.bioce1.2014.01.009
Barrow-McGee R, Kermorgant S(2014). Met endosomal signalling: in the right place, at the right time. Int J Biochem Cell Biol vol. 49, 69-74.
10.1016/j.biocel.2014.01.009
Ho-Yen CM, Green AR, Rakha EA, Brentnall AR, Ellis IO, Kermorgant S, Jones JL(2014). C-Met in invasive breast cancer: is there a relationship with the basal-like subtype?. Cancer vol. 120, (2) 163-171.
10.1002/cncr.28386
Barrow R, Joffre C, Ménard L, Kermorgant S(2014). Measuring the role for Met endosomal signaling in tumorigenesis. Methods Enzymol vol. 535, 121-140.
10.1016/B978-0-12-397925-4.00008-0
Radtke S, Milanovic M, Rossé C, De Rycker M, Lachmann S, Hibbert A, Kermorgant S, Parker PJ(2013). ERK2 but not ERK1 mediates HGF-induced motility in non-small cell lung carcinoma cell lines. J Cell Sci vol. 126, (Pt 11) 2381-2391.
10.1242/jcs.115832
Ho-Yen C, Bowen RL, Kermorgant S, Jones JL(2013). Comment on 'High MET expression is an adverse prognostic factor in patients with triple-negative breast cancer'. Br J Cancer vol. 108, (10) 2195-2196.
10.1038/bjc.2013.249
Ho-Yen C, Green A, Ellis I, Kermorgant S, Jones LJ (2012). C-Met Expression Correlates with Molecular Sub-type and Outcome in Invasive Breast Cancer. JOURNAL OF PATHOLOGY. vol. 228, S16-S16.
Milanovic M, Radtke S, Peel N, Howell M, Carrière V, Joffre C, Kermorgant S, Parker PJ(2012). Anomalous inhibition of c-Met by the kinesin inhibitor aurintricarboxylic acid. Int J Cancer vol. 130, (5) 1060-1070.
10.1002/ijc.26066
Bowen RL, Ho-Yen C, Vaziri R, Hulit J, Ryan D, Ornstein M, White Y, Choy C et al. (2011). C-met Defines a Distinct Subset of Triple Negative Breast Cancer in British Black Women. JOURNAL OF PATHOLOGY. vol. 224, S21-S21.
Joffre C, Barrow R, Ménard L, Calleja V, Hart IR, Kermorgant S(2011). A direct role for Met endocytosis in tumorigenesis. Nat Cell Biol vol. 13, (7) 827-837.
10.1038/ncb2257
Reynolds LE, Watson AR, Baker M, Jones TA, D'Amico G, Robinson SD, Joffre C, Garrido-Urbani S et al.(2010). Tumour angiogenesis is reduced in the Tc1 mouse model of Down's syndrome (vol 465, pg 813, 2010). NATURE vol. 466, (7304)
10.1038/nature09281
Reynolds LE, Watson AR, Baker M, Jones TA, D'Amico G, Robinson SD, Joffre C, Garrido-Urbani S et al.(2010). Tumour angiogenesis is reduced in the Tc1 mouse model of Down's syndrome. Nature vol. 465, (7299) 813-817.
10.1038/nature09106
Kermorgant S, Nevo J, Ivaska J(2010). Smart targeting of EGFR in lung cancer. PHARMACOGENOMICS vol. 11, (6) 743-744.
10.2217/pgs.10.78
Barrow R, Menard L, Kermorgant S (2010). c-Met endosomal signalling and breast cancer cell migration. EJC SUPPLEMENTS. vol. 8, 116-116.
10.1016/S1359-6349(10)71255-6
Rosse C, Linch M, Kermorgant S, Cameron AJM, Boeckeler K, Parker PJ(2010). PKC and the control of localized signal dynamics. Nat Rev Mol Cell Biol vol. 11, (2) 103-112.
10.1038/nrm2847
Kermorgant S, Parker PJ(2008). Receptor trafficking controls weak signal delivery: a strategy used by c-Met for STAT3 nuclear accumulation. J Cell Biol vol. 182, (5) 855-863.
10.1083/jcb.200806076
Aparicio T, Kermorgant S, Darmoul D, Guilmeau S, Hormi K, Mahieu-Caputo D, Lehy T(2005). Leptin and Ob-Rb receptor isoform in the human digestive tract during fetal development. J CLIN ENDOCR METAB vol. 90, (11) 6177-6184.
10.1210/jc.2005-1498
Kermorgant S, Parker PJ(2005). c-met signalling - Spatio-temporal decisions. CELL CYCLE vol. 4, (3) 352-355.
10.4161/cc.4.3.1596
Kermorgant S, Zicha D, Parker PJ(2004). PKC controls HGF-dependent c-Met traffic, signalling and cell migration. EMBO J vol. 23, (19) 3721-3734.
10.1038/sj.emboj.7600396
Casamassima A, Durgan J, Iturrioz X, Jevons A, Kermorgant S, Saurin A, Sipeki S, Parker P (2004). PKC superfamily - localised action and complex assembly. FASEB JOURNAL. vol. 18, C122-C122.
Kermorgant S, Zicha D, Parker PJ(2003). Protein kinase C controls microtubule-based traffic but not proteasomal degradation of c-Met. J Biol Chem vol. 278, (31) 28921-28929.
10.1074/jbc.M302116200
Ivaska J, Kermorgant S, Whelan R, Parsons M, Ng T, Parker PJ(2003). Integrin-protein kinase C relationships. Biochem Soc Trans vol. 31, (Pt 1) 90-93.
10.1042/bst0310090
Walker F, Kermorgant S, Daraï E, Madelenat P, Cremieux AC, Hénin D, Lehy T(2003). Hepatocyte growth factor and c-Met in cervical intraepithelial neoplasia: overexpression of proteins associated with oncogenic human papillomavirus and human immunodeficiency virus. Clin Cancer Res vol. 9, (1) 273-284.
Kermorgant S, Dessirier V, Lewin MJM, Lehy T(2002). HGF upregulates and modifies subcellular distribution of proteins in colon cancer cell enterocytic differentiation (vol 281, pg G1068, 2001). AM J PHYSIOL-GASTR L vol. 282, (3) GA2-GA2.
Goïot H, Attoub S, Kermorgant S, Laigneau JP, Lardeux B, Lehy T, Lewin MJ, Bado A(2001). Antral mucosa expresses functional leptin receptors coupled to STAT-3 signaling, which is involved in the control of gastric secretions in the rat. Gastroenterology vol. 121, (6) 1417-1427.
10.1053/gast.2001.29581
Kermorgant S, Dessirier V, Lewin MJ, Lehy T(2001). HGF upregulates and modifies subcellular distribution of proteins in colon cancer cell enterocytic differentiation. Am J Physiol Gastrointest Liver Physiol vol. 281, (4) G1068-G1080.
10.1152/ajpgi.2001.281.4.G1068
Kermorgant S, Lehy T(2001). Glycine-extended gastrin promotes the invasiveness of human colon cancer cells. BIOCHEM BIOPH RES CO vol. 285, (1) 136-141.
10.1006/bbrc.2001.5132
Kermorgant S, Aparicio T, Dessirier V, Lewin MJ, Lehy T(2001). Hepatocyte growth factor induces colonic cancer cell invasiveness via enhanced motility and protease overproduction. Evidence for PI3 kinase and PKC involvement. Carcinogenesis vol. 22, (7) 1035-1042.
10.1093/carcin/22.7.1035
Return to top